Shares of Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) hit a new 52-week high on Thursday . The stock traded as high as $23.52 and last traded at $23.00, with a volume of 50870 shares trading hands. The stock had previously closed at $23.04.
Analyst Upgrades and Downgrades
Separately, JPMorgan Chase & Co. assumed coverage on shares of Ascentage Pharma Group International in a report on Thursday, March 27th. They issued an “overweight” rating on the stock.
Read Our Latest Stock Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Trading Down 9.2 %
About Ascentage Pharma Group International
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More
- Five stocks we like better than Ascentage Pharma Group International
- A Deeper Look at Bid-Ask Spreads
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- EV Stocks and How to Profit from Them
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- Why Invest in High-Yield Dividend Stocks?
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
